Phase 3 Trial of Investigational Heart-Attack Drug Zalunfiban Shows Positive Results

Promising data from a pivotal Phase 3 trial of the investigational heart-attack drug zalunfiban (Disaggpro™) were presented during the late-breaking sessions at the American Heart Association Scientific Sessions in New Orleans. The study, known as CeleBrate, met its primary efficacy and safety endpoints in patients with ST-elevation myocardial infarction (STEMI).

The program received support from the Harrington Discovery Institute at University Hospitals, a philanthropic organization focused on advancing academic discoveries into new medicines.

A Next-Generation Emergency Antiplatelet Option

Zalunfiban is a next-generation GPIIb/IIIa inhibitor designed specifically for use by first responders and emergency room clinicians. The drug targets the platelet GPIIb/IIIa receptor, reducing clot formation or helping reopen blocked arteries.

It is delivered via subcutaneous injection, and its antiplatelet effects dissipate within two hours, a feature intended to minimize interference with later interventional procedures.

Academic Discovery Advanced Toward Clinical Use

The lead inventor, Barry Coller, MD, vice president for medical affairs and physician-in-chief at The Rockefeller University, co-founded CeleCor and helped guide the molecule from discovery to clinical testing.

Dr. Coller received the Harrington Discovery Institute’s physician-scientist award in 2015, which provided expert drug-development guidance, grant support, and strategic input—including decisions on administration route and early reimbursement planning.

“These contributions were instrumental in attracting new funding and advancing this medication into clinical trials,” Dr. Coller said.

Harrington Discovery Institute’s Broader Impact

Since its founding, the organization has supported:

• 217 drug programs in development
• 74 academic institutions
• 43 company launches
• 23 clinical candidates
• 15 licensing agreements

“Our mission is to propel promising academic discoveries into medicines for patients,” said Jonathan S. Stamler, MD, President and Co-Founder of Harrington Discovery Institute. “Dr. Coller’s work exemplifies that mission.”

Inside the CeleBrate Study

CeleBrate was a pivotal Phase 3, randomized, placebo-controlled trial evaluating a single subcutaneous dose of zalunfiban in STEMI patients treated before hospital arrival or in emergency departments.

Key details include:

• 2,467 patients enrolled
• 45 sites across the U.S., Canada, Mexico, and Europe

Prospective, blinded study design focused on rapid treatment in acute cardiac events

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!